Reforming the Orphan Drug Act for the 21st Century

N Engl J Med. 2019 Jul 11;381(2):106-108. doi: 10.1056/NEJMp1902943.

Authors

Ameet Sarpatwari¹, Aaron S Kesselheim¹

Affiliation

¹ From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

PMID: 31291512
DOI: 10.1056/NEJMp1902943

No abstract available

MeSH terms

Drug Costs
Drug Development / economics
Drug Development / legislation & jurisprudence*
Drug Industry / economics*
Drug Industry / legislation & jurisprudence
Drugs, Generic
Health Care Reform
Humans
Orphan Drug Production / legislation & jurisprudence*
Patents as Topic / legislation & jurisprudence
Rare Diseases / drug therapy
Rare Diseases / economics
Research Support as Topic / economics
Research Support as Topic / legislation & jurisprudence
United States

Substances

Drugs, Generic